Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy

Cancer Investigation

Volumn 19, Issue 4, 2001, Pages 424-436

  Gabizon, A A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Animal tumors; Anthracyclines; Chemotherapy; Doxorubicin; Drug delivery; Human cancer; Liposomes; Pharmacokinetics; Stealth; Targeting; Therapeutics; Toxicity

Indexed keywords

ANTIBODY; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; LIPOSOME; MACROGOL; NAVELBINE; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; VALSPODAR; VINCRISTINE;

ALOPECIA; ANAPHYLAXIS; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN; KAPOSI SARCOMA; MUCOSA INFLAMMATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALOPECIA; ANAPHYLAXIS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BREAST NEOPLASMS; CARDIOMYOPATHIES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOGS; DOXORUBICIN; DRUG CARRIERS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG SYNERGISM; FEMALE; FORECASTING; HALF-LIFE; HUMANS; LETHAL DOSE 50; LIPOSOMES; MACROPHAGES; MAXIMUM TOLERATED DOSE; MICE; NAUSEA; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RATS; RETICULOENDOTHELIAL SYSTEM; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; SOLUBILITY; STOMATITIS; SUSPENSIONS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035005359     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100103136     Document Type: Review

References (76)

1. Disease management of solid tumors and the emerging role of pegylated liposomal doxorubicin
2. Single-agent pegylated liposomal doxorubicin in cancer: Current status and furture applications
3. Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy
4. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases
5. Gelation of liposome interior. A novel method for drug encapsulation
6. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies
7. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size
8. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs
9. Pharmacological-toxicogical expert report - Caelyx™ (Stealth® liposomal doxorubicin HCl)
10. Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor-bearing animals
11. Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma
12. Polyethylene-glycol-coated (Pegylated) liposomal doxorubicin- rationale for use in solid tumors
13. Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines
14. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in c-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial?
15. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes
16. Preclinical studies with doxorubicin encapsulated in polyethyl-eneglycol-coated liposomes
17. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating pegylated liposomes
18. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
19. Pegylated liposomal doxorubicin: Scientific rationale and preclinical pharmacology
20. Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
21. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast cancer
22. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
23. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors
24. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
25. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
26. Treatment of advanced breast cancer with sterically-stabilized liposomal doxorubicin: Results of a multicenter phase II trial
27. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
28. EORTC 10968: Phase I study of caelyx at six week intervals in patients with metastatic breast cancer
29. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors
30. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™)
31. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: Evidence for anti-lipid antibodies and alternate pathway activation
32. Doxil (Caelyx): An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
33. Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes
34. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
35. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin
36. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin-containing pegylated (stealth) liposomes: A randomized, double-blind clinical trial using a canine model
37. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
38. 2
39. Lack of vesicant injury following extravasation of liposomal doxorubicin
40. Doxil extravasation injury: A case report
41. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma
42. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
43. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
44. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
45. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma
46. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
47. Interim analysis of a phase III randomized trial of doxil/caelyx versus topotecan in the treatment of patients with relapsed ovarian cancer
48. Phase I studies of doxil combined with cisplatin: Efficacy in epithelial ovarian and fallopian tube cancers
49. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
50. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
51. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy
52. A phase II study of doxil (Liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas
53. A randomised phase II trial of caelyx®/doxil® versus doxorubicin in advanced or metastatic soft tissue sarcomas (STS) - An EORTC soft tissue and bone sarcoma group (STBSG) trial
54. Phase I study of caelyx (Doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
55. Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin
56. Phase I trial of doxil plus cisplatin in patients with advanced malignancies
57. Phase II trial to evaluate the safety and tolerability of caelyx® (Doxil®) in combination with paclitaxel in the treatment of metastatic cancer
58. A phase I study of taxotere and doxil in patients with advanced malignancies
59. Phase I study of doxil and vinorelbine in metastatic breast cancer
60. Constant infusion schedule for adriamycin: A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system
61. Continuous venous infusion of doxorubicin in advanced sarcomas
62. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR)
63. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin-2
64. Antitumor activity of herceptin™ in combination with doxil® or nonencapsulated doxorubicin in a HER2 positive breast cancer model
65. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
66. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma
67. Folate-mediated targeting of anti-neoplastic drugs, imaging agents, and nucleic acids to cancer cells
68. Development of anti-p185HER2 immunoliposomes for cancer therapy
69. Targeting of stealth liposomes to erbB2 (Her/2) receptor: In vitro and in vivo studies
70. Preclinical and clinical experience with a doxorubicin-liposome preparation
71. Clinical pharmacology and anti-tumor efficacy of doxil (Pegylated liposomal doxorubicin)